Stoke and Biogen enter $165M upfront collaboration for zorevunersen (Dravet syndrome)

Stoke Therapeutics, Inc.

Stoke receives $165M upfront; eligible for up to $385M in milestones and low-double-digit to high-teen royalties.
Stoke retains exclusive rights in US, Canada, Mexico; Biogen gets rest-of-world commercialization rights.
Phase 3 EMPEROR study to start Q2 2025 with pivotal data readout expected 2H 2027.
Cash runway extended to mid-2028, including upfront payment and other eligible cash flows.
Zorevunersen has FDA Breakthrough Therapy designation; Phase 1/2a showed substantial seizure reduction and cognitive improvements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.